CD8A and neoplasm: The univariate analysis revealed that tumor size ≥ 2 cm (P < 0.001), low differentiation (P = 0.01), clinical stages at IV (P < 0.001), brain metastases (P < 0.001), bone metastases (P = 0.028), PD-L1 expression < 1% (P < 0.001), and lower baseline AC of CD3+ (P < 0.001), CD4+ (P < 0.001), CD8+ (P < 0.001), B AC (P < 0.001) and NK cells (P = 0.002) were associated with poorer efficacy.